[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349715-105":59,"doc-detail-349715-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","case-report-spatiotemporal-her2-heterogeneity-in-afp-producing-gastric-cancer-navigating-long-term-survival-with-molecularly-guided-therapy-in-a-refractory-case","Case report: Spatiotemporal HER2 heterogeneity in AFP-producing gastric cancer - navigating long-term survival with molecularly-guided therapy in a refractory case","","Alpha-fetoprotein-producing gastric cancer (AFPGC) is a rare, aggressive subtype with limited options and poor outcomes. This case report describes a metastatic AFPGC patient with dynamic spatiotemporal HER2 heterogeneity. After progression on first-line FLOT chemotherapy, second-line apatinib plus a PD-1 inhibitor was used, followed by third-line HER2-targeted DP303c ADC after HER2 conversion. AFP levels normalized and partial response persisted despite ADC discontinuation for neurotoxicity, leading to 79 months overall survival.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/case-report-spatiotemporal-her2-heterogeneity-in-afp-producing-gastric-cancer-navigating-long-term-survival-with-molecularly-guided-therapy-in-a-refractory-case/349715/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/case-report-spatiotemporal-her2-heterogeneity-in-afp-producing-gastric-cancer-navigating-long-term-survival-with-molecularly-guided-therapy-in-a-refractory-case/349715.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What makes AFP-producing gastric cancer (AFPGC) challenging to treat?","Question",{"text":112,"@type":113},"AFPGC is rare and aggressive, with a poor prognosis and limited therapeutic options. Its metastatic pattern, especially frequent liver involvement, contributes to unfavorable outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was HER2 heterogeneity detected and what changed over time?",{"text":117,"@type":113},"HER2 status was assessed at different disease stages. At progression, lymph node biopsy showed HER2 conversion from 1+ to 3+, indicating spatiotemporal heterogeneity.",{"name":119,"@type":110,"acceptedAnswer":120},"What treatment sequence supported long-term survival in this case?",{"text":121,"@type":113},"After FLOT chemotherapy progression, the patient received apatinib plus a PD-1 inhibitor. Upon HER2 conversion, a third-line anti-HER2 antibody-drug conjugate (DP303c) was given, resulting in partial response and normalized AFP even after treatment discontinuation due to neurotoxicity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349715,1790867244,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","TYPE Case Report  \nPUBLISHED 02 January 2026  \nDOI 10.3389/fimmu.2025.1696069  \nOPEN ACCESS  \nEDITED BY  \nRahul Shivahare,  \nThe Ohio State University, United States  \nREVIEWED BY  \nMegha Das,  \nUniversity of Miami, United States Ravi Sonkar,  \nBoston University, United States Nagaishwarya Moka,  \nLincoln Memorial University, United States  \n*CORRESPONDENCE  \nQian Dong  \n [dongqian08@163.com](dongqian08@163.com)[ ](dongqian08@163.com)Jingdong Zhang  \n[jdzhang@cancerhosp-ln-cmu.com](jdzhang@cancerhosp-ln-cmu.com)  \n†These authors have contributed equally to this work  \nRECEIVED 31 August 2025  \nREVISED 24 November 2025  \nACCEPTED 28 November 2025  \nPUBLISHED 02 January 2026  \nCITATION  \nDiao Y, Yin H, Sun X, Dong Q and Zhang J (2026) Case report: Spatiotemporal HER2 heterogeneity in AFP-producing gastric cancer: navigating long-term survival with molecularly-guided therapy in a refractory case.  \nFront. Immunol. 16:1696069 .  \ndoi: 10.3389/fimmu.2025.1696069  \nCOPYRIGHT  \n© 2026 Diao, Yin, Sun, Dong and Zhang. This isan open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nCase report: Spatiotemporal HER2 heterogeneity in AFPproducing gastric cancer:  \nnavigating long-term survival with molecularly-guided therapy in a refractory case  \nYanwen Diao †, Haobo Yin †, Xin Sun, Qian Dong* and Jingdong Zhang*  \nMedical Oncology Department of Gastrointestinal Tumors, Liaoning Cancer Hospital and Institute, Liaoning Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Shenyang, China  \nAlpha-fetoprotein-producing gastric cancer (AFPGC) is a rare, aggressive subtype with poor prognosis. We report a metastatic AFPGC case showing spatiotemporal human epidermal growth factor receptor 2 (HER2) heterogeneity. Following progression on ﬁrst-line FLOT chemotherapy, the 65-year-old male received second-line apatinib plus programmed death-1 (PD-1) inhibitor. At progression (27 months), a lymph node biopsy revealed HER2 conversion from 1+ to 3 + . Thirdline anti-HER2 antibody-drug conjugate (ADC) DP303c rapidly achieved partial response with normalized AFP. Despite treatment discontinuation due toneurotoxicity after 5 cycles, response persisted. Overall survival reached 79 months. This case highlights: 1) efﬁcacy of anti-angiogenic and immunotherapy in AFPGC; 2) necessity of re-biopsy for detecting HER2 heterogeneity; and 3) potent activity of ADCs against HER2-converted metastases, enabling remarkable survival through sequential precision therapy.  \nKEYWORDS  \nheterogeneity, alpha-fetoprotein-producing gastric cancer, human epidermal growthfactor receptor 2, immunotherapy, anti-angiogenesis therapy  \nIntroduction  \nGastric cancer (GC) remains highly prevalent in China, with advanced disease exhibiting marked heterogeneity and poor prognosis, underscoring the need for molecular-level insights to guide treatment. AFPGC, a rare subtype representing 1.3%– 15% of cases globally (1), is characterized by frequent liver metastasis, limited therapeutic options, and an unfavorable outlook. HER2 serves as a key therapeutic target in GC, though its heterogeneity—evidenced by discordance rates of 45%–79% by immunohistochemistry  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n(IHC) and 23%–54% by in situ hybridization (ISH) (2),—complicates patient stratiﬁcation and precise targeting. Here, we present a case of metastatic AFPGC with dynamic spatiotemporal HER2 heterogeneity, in which sequential molecularly-guided therapy enabled prolonged survival.  \nCase ","cbCainV4PVz0KeSs","https://ap.wps.com/l/cbCainV4PVz0KeSs","pdf",12580566,"English","# Introduction\n# Case presentation","[{\"question\":\"What makes AFP-producing gastric cancer (AFPGC) challenging to treat?\",\"answer\":\"AFPGC is rare and aggressive, with a poor prognosis and limited therapeutic options. Its metastatic pattern, especially frequent liver involvement, contributes to unfavorable outcomes.\"},{\"question\":\"How was HER2 heterogeneity detected and what changed over time?\",\"answer\":\"HER2 status was assessed at different disease stages. At progression, lymph node biopsy showed HER2 conversion from 1+ to 3+, indicating spatiotemporal heterogeneity.\"},{\"question\":\"What treatment sequence supported long-term survival in this case?\",\"answer\":\"After FLOT chemotherapy progression, the patient received apatinib plus a PD-1 inhibitor. Upon HER2 conversion, a third-line anti-HER2 antibody-drug conjugate (DP303c) was given, resulting in partial response and normalized AFP even after treatment discontinuation due to neurotoxicity.\"}]","Case report: Spatiotemporal HER2 heterogeneity in AFP-producing gastric cancer - navigating long-term survival with molecularly-guided therapy in a refractory case | PDF",1790085192,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/572547eb67bc0ff37b8b81770fcfa50e.webp",983,1389,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1dc05cb6e25b15292559204f0d0187a3.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5b9153b8eb7ef760d6ff7074992b915.webp",981,1386,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/47dde10f410a1700ff1092b716e62821.webp",980,1385]